Answers are grounded in this paper and cite their sources.
Homologous recombination repair (HRR) alterations define a heterogeneous subgroup of metastatic castration-resistant prostate cancer. TALAPRO-2 established randomized benefit of talazoparib plus enzalutamide within HRR-deficient disease, but it did not determine whether treated HRR-deficient patients remain prognostically disadvantaged relative to biomarker-defined enzalutamide-alone reference groups. We performed exploratory trial-internal benchmarking using reconstructed individual patient data from published TALAPRO-2 Kaplan-Meier curves, with different endpoint-specific reference groups for radiographic progression-free survival (rPFS) and overall survival (OS). With enzalutamide alone, HRR-deficient disease had shorter rPFS than HRR-non-deficient disease (16.4 vs 22.3 months; HR 1.42, 95% CI 1.00-2.00) and shorter OS than disease with no HRR alteration detected (30.9 vs 37.7 months; HR 1.23, 95% CI 0.89-1.71). With talazoparib plus enzalutamide, corresponding medians were 27.9 and 45.8 months; cross-benchmark HRs were 0.73 (95% CI 0.50-1.07) and 0.66 (95% CI 0.46-0.96). These non-randomized comparisons are descriptive and do not establish equivalence, superiority, or prognostic normalization.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: